Key Investor Information

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

Legal & General Global Health and Pharmaceuticals Index Trust Unit Class C GBP Income - ISIN: GB00BJ2JPH90

The authorised fund manager of the Fund is Legal & General (Unit Trust Managers) Limited (the "Manager").

OBJECTIVES AND INVESTMENT POLICY

- The objective of the Fund is to track performance of the FTSE World Index -Health Care, the "**Benchmark Index**" on a net total return basis before fees and expenses are applied. Fund performance may differ from the Benchmark Index due to the deduction of fees and expenses and the impact
- of any tracking error factors. The Benchmark Index is comprised of shares in companies engaged in health, pharmaceuticals and biotechnology. The Fund seeks to replicate the Benchmark Index and its investments will
- closely match those that make up the Benchmark Index.
- The Fund will have at least 90% exposure (directly or through depositary receipts (a certificate issued by a bank representing shares in a foreign company such as American depositary receipts and global depositary receipts)) to assets that are included in the Benchmark Index.
- The Fund may also invest in shares which are reasonably expected to become part of the Benchmark Index in the near future or are an alternative to a constituent of the Benchmark Index, money market instruments (such as treasury bills), depositary receipts, cash, deposits and collective investment schemes, including those managed or operated by the Manager
- or an associate of the Manager. The Fund may use derivatives (contracts which have a value linked to the price of another asset) to:
- reduce risk or cost; or

RISK AND REWARD PROFILE

Lower Risk			Higher Risk			
Potentially	lower rewa	rds		Potentially higher rewards		
1	2	3	4	5	6	7

- The Risk and Reward Indicator table demonstrates where the Fund ranks in terms of its potential risk and reward. The higher the rank the greater the potential reward but the greater the risk of losing money. It is not guaranteed to remain the same and may change over time. It is based on historical data and may not be a reliable indication of the future risk profile of the Fund. The shaded area in the table above shows the Fund's ranking on the Risk and Reward Indicator.
- The Fund is in category 6 because it invests in company shares which are sensitive to variations in the stock market. The value of company shares can change substantially over short periods of time. Company shares are generally considered to be higher risk investments than bonds or cash. • Even a fund in the lowest category is not a risk free investment.
- . The value of your investment and any income you take from it may fall as well as rise and is not guaranteed. You might get back less than you invest
- Further information on the risks of investing in this fund is contained in the

· generate additional capital or income with no, or an acceptably low, level of risk

Other information:

- The Fund is passively managed as it tracks the Benchmark Index.
- Your units will be income units. Income from the Fund's investments will be paid out to you annually (as dividends). This will reduce your capital growth accordingly
- You can buy or sell units in this Fund on any business day. You need to contact us with your instruction before 3pm. This is the time we calculate unit prices for this Fund. If you contact us after 3pm, the units will be bought or sold at the next business day's price.
- The Fund's base currency is denominated in GBP.
- This Fund may be suitable for investors looking to invest in health, pharmaceuticals and biotechnology company shares as represented by the Benchmark Index.
- Although investors can take their money out at any time, this Fund may not be appropriate for those who plan to withdraw their money within five years. This Fund is not designed for investors who cannot afford more than a
- minimal loss of their investment. · If you do not understand this document we recommend you seek additional
- information to help you decide if this Fund is right for you.

Prospectus available at www.legalandgeneral.com/reports. The risk and reward indicator may not take account of the following risks of investing in the Fund:

- The return from this Fund is dependent on relatively few individual investments. This means that a fall in the value of an individual investment
- can have a major impact on the overall performance of the Fund. Most of the Fund holds investments from a particular market sector, that of health, pharmaceuticals and biotechnology. Funds like this can be more volatile than funds that invest across many market sectors. This is because the value of the Fund can go up and down more often and by larger amounts than funds that are spread more widely, especially in the short-term
- The Fund may have underlying investments that are valued in currencies that are different from GBP. Exchange rate fluctuations will impact the value of your investment. Currency hedging techniques may be applied to reduce this impact but may not entirely eliminate it.
- Derivatives are highly sensitive to changes in the value of the asset on which they are based and can increase the size of losses and gains.
- The Fund could lose money if any institutions providing services such as acting as counterparty to derivatives or other instruments, becomes unwilling or unable to meet its obligations to the Fund.



CHARGES


The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential return from your investment.

One-off charges taken before or after you invest				
Entry charge	0.00%			
Exit charge	0.00%			
This is the maximum that might be taken out of your money before it is invested.				

The price for buying and selling units is subject to a Dilution Adjustment See opposite

ppono.					
Charges taken from the fund over each year					
Ongoing charge	0.20%				
Charges taken from the fund under	arges taken from the fund under certain specific conditions				
Performance fee	None				

PAST PERFORMANCE



PRACTICAL INFORMATION

The trustee and depositary is Northern Trust Investor Services Limited.

You can obtain further information about the Fund including copies of its prospectus and the latest annual and semi-annual reports at www.legalandgeneral.com/reports. Paper copies of these documents are also available free of charge in English from Legal & General Investments, PO Box 6080, Wolverhampton WV1 9RB.

- Investors can get other practical information, including the latest prices, dilution adjustment and details of any other unit classes that are available, by calling us on 0370 050 0955 Monday to Friday between 9:00a.m. to 5:00p.m. Call charges will vary. This Fund is subject to the tax legislation of the United Kingdom, which may have an impact on each investor's personal tax position.
- Legal & General (Unit Trust Managers) Limited may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Prospectus for the Fund. Details of our Remuneration Policy including our Remuneration Committee and how remuneration and benefits are calculated can be accessed from
- www.lgim.com/remuneration. A paper copy is also available free of charge upon request.

- There are no entry or exit charges.
- The ongoing charges figure is based on the latest available expenses at January 2023. This figure may vary from year to year. This Fund's ongoing charges include any charges made by any other
- funds it may invest in. They exclude portfolio transaction costs. The ongoing charges are taken from the Income of the Fund.
- Other costs
- Dilution adjustment: On any day, the prices for buying or selling units in this Fund are the same. The Fund manager calculates a single price for this Fund based on the mid-point between the buying and selling prices of the Fund's assets. In certain circumstances, the Fund manager can adjust this price to account for whether there is more money going into or coming out of the Fund. This is called a 'dilution adjustment
- This can vary but as an example for this Fund we estimate 0.10% for purchases and 0.08% for sales at 02 February 2023. The amount of the dilution adjustment may differ in future.

For more information about charges and costs, please see the charges and expenses section in the Fund's Prospectus, or visit our website at **www.legalandgeneral.com/chargesandfees**.

- Past performance is not a guide to future performance.
 The figures for the Fund take into account the ongoing charges and assume income (after any tax) is reinvested. The performance has been calculated in GBP
- The Fund may not replicate the performance of the Benchmark Index perfectly due to tracking errors such as expenses, tax and transaction costs incurred by the Fund, which are not included in the Index.
- The annual return is for a 12 month period ending 31 December.
- The Fund launched in 2000.
- This unit class launched in 2019.